EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Elemental Boron Nanoparticles for Boron-Neutron Capture Therapy of BT-474 Human Breast Cancer

Evgenii L Zavjalov, Linga D Romanenko, Olga I Kichakova iD, Anna I Kasatova iD, Polina A Kotelnikova iD, Dmitry S Petrunya iD, Ekaterina V Barmina iD, Kuder O Aiyyzhy, Artem A Laktionov iD, Sergei M Klimentov, Anton A Popov iD, Maria S Grigoryeva iD und 8 weitere

Nanomaterials · 07.08.2026 · 16 (16) · 973

DOI: 10.3390/nano16160973 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nanomaterials, online erschienen am 07.08.2026. Verfasst von Evgenii L Zavjalov und 19 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer remains one of the most common malignancies worldwide. Highly invasive HER2-positive breast cancer carries a high risk of metastasis and poses a significant therapeutic challenge. Boron neutron capture therapy (BNCT) may be an option for patients with this severe diagnosis. Here we evaluated the effectiveness of BNCT with elemental boron nanoparticles obtained by laser fragmentation and coated Silane-PEG-COOH and conjugated with the Affibody ZHER2:342 guide protein (BPs) against the HER2-positive breast cancer. The MTT assay after BNCT with BPs revealed an almost twofold reduction in surviving BT-474 tumor cells compared to the control group. The results of the clonogenic test showed totally death of BT-474 cells after BNCT with BPs at a concentration of 40 μg/mL in the culture medium. The same results was found for in vivo. In female SCID mice bearing BT-474 breast tumor xenografts, BNCT with intratumoral injection of BPs at a dose of 60 mg/kg led to a significant slowdown in xenograft growth beginning on the 17th day compared with control animals and the 39th day compared with irradiated females. A single intratumoral administration of BPs at a dose of 60 mg/kg did not show toxic effects. Histological examinations did not reveal systemic accumulation of the studied BPs in major organs; instead BPs was selectively retained within the xenografts and surrounding tissues. Thus, laser fragmented functionalized with Silane-PEG-COOH and the Affibody ZHER2:342 (BPs B-PEG-AFF) represent a promising platform for boron delivery in targeted BNCT applications.

Schlagwörter

Stichwörter der Autor:innen

AffibodyBT-474HER2SCIDboron neutron capture therapy (BNCT)breast cancerelemental boron particles (BPs)in vitroin vivomicexenografts

Autor:innen und Institutionen

  • Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia.
  • P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119333, Russia.
  • Budker Institute of Nuclear Physics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia.
  • Novosibirsk State University, Novosibirsk 630090, Russia.
  • Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow 117437, Russia.
  • National Research Centre "Kurchatov Institute", Moscow 123182, Russia.

ORCID-Profile: Olga I Kichakova, Anna I Kasatova, Polina A Kotelnikova, Dmitry S Petrunya, Ekaterina V Barmina, Artem A Laktionov, Anton A Popov, Maria S Grigoryeva, Egor I Mavreshko, Danila A Pokhorukov, Sergey Yu Taskaev, Sergey M Deyev

Förderung

  • Russian Science Foundation

Zitieren

APA

Zavjalov, E. L., Romanenko, L. D., Kichakova, O. I., Kasatova, A. I., Kotelnikova, P. A., Petrunya, D. S., Barmina, E. V., Aiyyzhy, K. O., Laktionov, A. A., Klimentov, S. M., Popov, A. A., Grigoryeva, M. S., Bykov, T. A., Podolyako, V. V., Fronya, A. A., Mavreshko, E. I., Pokhorukov, D. A., Taskaev, S. Y., Deyev, S. M., & Zavestovskaya, I. N. (2026). Elemental Boron Nanoparticles for Boron-Neutron Capture Therapy of BT-474 Human Breast Cancer. Nanomaterials, 16(16), 973. https://doi.org/10.3390/nano16160973

Vancouver

Zavjalov EL, Romanenko LD, Kichakova OI, Kasatova AI, Kotelnikova PA, Petrunya DS, et al. Elemental Boron Nanoparticles for Boron-Neutron Capture Therapy of BT-474 Human Breast Cancer. Nanomaterials. 2026;16(16):973. doi:10.3390/nano16160973

BibTeX
@article{Zavjalov2026,
  author = {Zavjalov, Evgenii L and Romanenko, Linga D and Kichakova, Olga I and Kasatova, Anna I and Kotelnikova, Polina A and Petrunya, Dmitry S and Barmina, Ekaterina V and Aiyyzhy, Kuder O and Laktionov, Artem A and Klimentov, Sergei M and Popov, Anton A and Grigoryeva, Maria S and Bykov, Timofey A and Podolyako, Vasilisa V and Fronya, Anastasia A and Mavreshko, Egor I and Pokhorukov, Danila A and Taskaev, Sergey Yu and Deyev, Sergey M and Zavestovskaya, Irina N},
  title = {Elemental Boron Nanoparticles for Boron-Neutron Capture Therapy of BT-474 Human Breast Cancer},
  journal = {Nanomaterials},
  year = {2026},
  volume = {16},
  number = {16},
  pages = {973},
  doi = {10.3390/nano16160973}
}
Kostenlos starten →